| Summary: | Chung-Shien Lee,1,2 Matthew Milone,3 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, Queens, NY, USA; 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Lake Success, NY, USA; 3Pharmacy Department, Long Island Jewish Medical Center, New Hyde Park, NY, USACorrespondence: Nagashree Seetharamu Email nseetharamu@northwell.eduAbstract: The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib has become the preferred EGFR tyrosine kinase inhibitor (TKIs) for patients with these mutations after demonstrating superior efficacy compared to first generation EGFR TKIs, such as erlotinib and gefitinib. More recently osimertinib has also shown to be beneficial in patients with resectable NSCLC harboring EGFR mutations irrespective of whether they received adjuvant chemotherapy or not. The drug is now FDA approved in this setting. With osimertinib being used more commonly in earlier stage and front-line settings, we are more likely to see patients who develop resistance to this drug. The aim of this review is to provide a comprehensive review of the data with osimertinib in EGFR mutation positive NSCLC, potential resistance mechanisms and an overview of key ongoing clinical trials.Keywords: non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitor, osimertinib
|
|---|
